Neuronetics shares are trading lower after the company reported worse-than-expected Q2 financial results and issued Q3 revenue guidance below estimates. Also, the company announced it will acquire Greenbrook TMS in an all-stock transaction.
Portfolio Pulse from Benzinga Newsdesk
Neuronetics shares are trading lower after the company reported worse-than-expected Q2 financial results and issued Q3 revenue guidance below estimates. Additionally, Neuronetics announced it will acquire Greenbrook TMS in an all-stock transaction.
August 12, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neuronetics shares are trading lower due to worse-than-expected Q2 financial results and lower Q3 revenue guidance. The company also announced an all-stock acquisition of Greenbrook TMS.
The disappointing Q2 financial results and lower Q3 revenue guidance are likely to negatively impact investor sentiment in the short term. The acquisition of Greenbrook TMS, while potentially beneficial in the long run, adds uncertainty and may not immediately offset the negative impact of the earnings report.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100